Tumor Response Prediction in 90Y Radioembolization with PET-based Radiomics Features and Absorbed Dose Metrics

Lise Wei (liswei@umich.edu)  
University of Michigan  https://orcid.org/0000-0001-7226-2091

Can Cui  
Vanderbilt University

Jiarui Xu  
Virginia Tech University

Ravi Kaza  
University of Michigan Rogel Cancer Center

Issam El Naqa  
University of Michigan

Yuni K Dewaraja  
University of Michigan

Original research

Keywords: 90Y, PET Imaging, liver cancer, radiomics, absorbed dose, radioembolization

Posted Date: June 5th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-19467/v2

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License

Version of Record: A version of this preprint was published at EJNMMI Physics on December 9th, 2020. See the published version at https://doi.org/10.1186/s40658-020-00340-9.
Abstract

**Purpose** Evaluate whether lesion radiomics features and absorbed dose metrics extracted from post-therapy $^{90}$Y PET can be integrated to better predict outcome in microsphere radioembolization of liver malignancies.

**Methods** Given the noisy nature of $^{90}$Y PET, first, a liver phantom study with repeated acquisitions and varying reconstruction parameters was used to identify a subset of robust radiomics features for the patient analysis. In 36 radioembolization procedures, $^{90}$Y PET/CT was performed within a couple of hours to extract 46 radiomics features and estimate absorbed dose in 105 primary and metastatic liver lesions. Robust radiomics modeling was based on bootstrapped multivariate logistic regression with shrinkage regularization (LASSO) and Cox regression with LASSO. Nested cross-validation and bootstrap resampling were used for optimal parameter/feature selection and for guarding against overfitting risks. Spearman rank correlation was used to analyze feature associations. Area under the receiver-operating characteristics curve (AUC) was used for lesion response (at first follow-up) analysis while Kaplan-Meier plots and c-index were used to assess progression model performance. Models with absorbed dose only, radiomics only and combined models were developed to predict lesion outcome.

**Results** The phantom study identified 15/46 reproducible and robust radiomics features that were subsequently used in the patient models. A lesion response model with zone percentage (ZP) and mean absorbed dose achieved an AUC of 0.729 (95%CI: 0.702-0.758) and a progression model with zone size nonuniformity (ZSN) and absorbed dose achieved a c-index of 0.803 (95% CI: 0.790-0.815) on nested cross validation (CV). The combined models outperformed the radiomics only and absorbed dose only models.

**Conclusion** We have developed new lesion-level response and progression models using textural radiomics features, derived from $^{90}$Y PET combined with mean absorbed dose for predicting outcome in radioembolization. These encouraging results may need further validation in independent datasets prior to clinical adoption.

Introduction

Delivering external radiation to multifocal/large liver tumors is a challenging task due to the damage of surrounding normal liver parenchyma. Hence, when disease burden is high, selective internal radiation delivery is preferred. Transarterial radioembolization (RE), with preferential delivery of glass or resin microspheres embedded with beta-emitting $^{90}$Y to hepatic tumors is an established treatment for unresectable hepatocellular carcinoma (uHCC) and liver metastases [1, 2]. Ability to predict lesion-level response immediately after therapy can facilitate adaptive therapies following RE by selecting lesion(s) predicted to be non-responding to the initial treatment for subsequent highly focal external stereotactic radiation.

Radiomics, a branch of quantitative image analysis, can capture heterogeneity characteristics of regions of interest (ROIs) by extracting relevant features from medical images (CT, MR, PET) has been widely explored in the literature and shown to provide predictive capability of treatment response in different cancers [3-11]. Specifically, in patients undergoing transarterial $^{90}$Y radioembolization in uHCC, Blanc-Durand et al. showed
that pre-treatment FDG-PET derived radiomics features (strength for PFS, variance, strength, low intensity run short emphasis and contrast for OS) for whole liver are independent negative predictors for progression-free survival (PFS) and overall survival (OS) [12]. Gensure et al. found tumor contrast-enhanced CT based texton and local binary pattern (LBP) features both achieve high accuracy in discriminating patient response to radioembolization (RE) with $^{90}$Y resin microspheres in terms of serologic response and survival status [13]. Recent studies, by our group and others have reported on the association between post-therapy $^{90}$Y imaging derived lesion absorbed dose and outcome (response, survival) in patients treated with $^{90}$Y radioembolization for primary and metastatic liver cancer [14-18]. However, to our knowledge, our current study is the first investigation to combine lesion radiomics features with absorbed dose metrics to predict outcome. Furthermore, our study relies on radiomics features from post-treatment $^{90}$Y PET imaging, unlike prior studies that used conventional FDG PET-derived features, which makes it unique in this respect. Compared with FDG-PET, $^{90}$Y PET is considerably more noisy due to the low true coincidence rate associated with a low yield-positron in the presence of high random coincidence rates [19]. However, recent $^{90}$Y PET/CT studies have reported good quantitative accuracy and contrast-to-noise for dosimetry applications, using time-of-flight (TOF), longer acquisitions, optimized reconstruction parameters and partial volume correction [18, 20]. Although $^{90}$Y can also be imaged by bremsstrahlung SPECT, the poor spatial resolution and challenges of correcting for bremsstrahlung scatter, makes $^{90}$Y PET potentially better suited for radiomics analysis.

A major challenge of radiomics modeling especially with limited data is the robustness of the extracted features, as highlighted in recent review articles [21-23]. Variabilities can result from contouring, reconstruction algorithms, filtering, even different scans with the same setting. Another challenge is the risk of overfitting when dealing with relatively small datasets. Therefore, in this study both issues are addressed by: (1) conducting a phantom study to identify robust features, particularly to assess reconstruction and variability issues; and (2) applying a modified LASSO approach with bootstrap resampling for robust modeling. To mitigate analysis bias, nested cross-validation was used to train (feature selection, model construction) and test the outcome model (evaluation).

**Materials And Methods**

**Patient cohort**

The study included patients with primary and secondary intrahepatic malignancies who had $^{90}$Y PET/CT imaging performed after $^{90}$Y radioembolization with glass microspheres (Theraspheres) at University of Michigan (UM) Medical Center as part of an ongoing dosimetry research study. Selection criteria for $^{90}$Y PET/CT imaging were: well defined lesions >2 mL, ability to undergo imaging, follow-up at UM and informed consent. The patient and lesion characteristics for the 36 lobar treatments (30 patients, 105 lesions, 6 patients had treatment to right and left lobes at different time points.) are summarized in Supplemental Table 1. The treating physician followed standard guidelines to deliver 80-150 Gy to the treated liver with empirical adjustments within this range based on clinical factors. The $^{90}$Y PET/CT imaging was approved by the institutional review board, and all subjects signed an informed consent form.

$^{90}$Y PET/CT Imaging and dosimetry
Images were acquired on a Siemens Biograph mCT PET/CT within a couple of hours of the RE procedure (prior to discharge) with an acquisition time of ~30 minutes to cover the entire liver and partial lung. PET reconstruction parameters were selected based on phantom studies considering both activity recovery and noise: 1 iteration, 21 subsets of 3D OS-EM with time-of-flight and resolution recovery and a 5 mm Gaussian post-filter [18]. The PET matrix size was 200×200 with a pixel size 4.07×4.07 mm and a slice thickness of 3 mm. The CT was performed in low dose mode (120 kVp; 80 mAs) during free-breathing. The CT matrix size was 512×512 with a pixel size of 0.97×0.97 mm and a slice thickness of 2 mm.

PET images were transformed to CT-space and the CT-derived density map were input to our DPM Monte Carlo code [18] to generate dose-rate maps that were converted into absorbed dose maps by accounting for $^{90}\text{Y}$ physical decay. Mean absorbed doses to segmented lesions were reported following partial volume correction based on volume-dependent recovery coefficients, determined from a phantom study [18].

**Radiomics: lesion segmentation, PET data preprocessing and feature extraction**

Lesion segmentation was performed on diagnostic quality contrast enhanced baseline CT or MRI by a radiologist specializing in hepatic malignancies (RK), which is considered a gold standard. Note that variability due to contouring can be a source of error, but has been addressed in several previous studies [6, 24, 25]. The diagnostic scan was then rigidly registered to the CT of the $^{90}\text{Y}$ PET/CT and the contours were transformed with fine tuning when mis-registration was evident on MIM (MIM Software Inc, Cleveland, OH). In some cases, where the lesions were well visualized on the non-contrast low-dose CT of the PET/CT they were directly defined on this CT in order to minimize mis-registration effects. Up to 5 (largest) lesions > 2 mL were segmented per patient.

Lesion contours and $^{90}\text{Y}$ PET images were input to an in-house developed (Matlab, MathWorks Inc., Natick, MA) radiomics toolbox (benchmarked by image biomarker standardization - ISBI) that run as an extension on MIM. Our radiomics code is shared at https://github.com/mvallieres/radiomics. All subsequent analyses were performed in MATLAB. First, a root-squared transform was applied to the PET images to reduce quantum noise effects [26].

The full intensity range of the tumor region was quantized to a smaller number of gray levels (Ng) before computation of the features. The quantization algorithm used is Lloyd-Max algorithm, which attempts to minimize the mean-squared quantization error of the output. Ng was experimentally chosen as 32 [27]. The features were extracted from 3D $^{90}\text{Y}$ PET images, which were interpolated to isotropic voxel size (0.97 mm). 46 features, including volume, one shape feature (sphericity), 4 global features, and 40 texture features from gray-level co-occurrence matrix (GLCM), gray-level run length matrix (GLRLM), gray-level size zone matrix (GLSZM), and neighborhood gray-tone difference matrix (NGTDM), were extracted. All the feature extraction followed the Image biomarker standardization initiative (IBSI) guidance [28]. These features represent the spectrum of commonly used features, especially in PET imaging [6, 29, 30]. We further opted for extraction parameters following the ISBI guidelines due to the limited sample size, we didn’t explore further parameterization or less commonly used features. Supplemental Table 2 presents the list of radiomics features used in this study.
Lesion-level Study Endpoints

Phantom study to assess radiomics feature repeatability and reproducibility

A $^{90}$Y PET/CT study with a liver/lung torso phantom consisting of a ‘warm’ liver compartment and three ‘hot’ lesion inserts (29 mL ellipsoid, 16 mL sphere, 8 mL sphere) with an insert-to-liver activity concentration ratio of 5:1 was performed. The total activity in the phantom was 1.9 GBq and the activity concentrations in the inserts were 6.0-7.3 MBq/mL and liver minus inserts was 1.2 MBq/mL. To assess radiomics feature repeatability 5 consecutive 30 min acquisitions under identical conditions were performed on the same PET/CT system as in the patient studies. To assess sensitivity to reconstruction parameters and filtering, each of the 5 scans were reconstructed with 1 and 2 OS-EM iterations (21 subsets) and with and without Gaussian post-filter. The activity concentrations, acquisition time and parameters used in the phantom study were chosen to reflect conditions for imaging following $^{90}$Y RE, hence, the noise-level was clinically relevant.

Statistical Analysis

1. Phantom feature robustness study

Concordance correlation coefficient (CCC) metric assumed each observation was independent as has been commonly reported in repeatability/reproducibility studies [22, 32]. Thus, in the robustness study of our extracted radiomics features, CCCs were computed for the different scans, different iterations, and with/without Gaussian filtering. For each of the 45 radiomics features (without volume), the resulting CCCs were averaged, and features with larger than 0.85 [22, 33-36] average CCC - robust radiomics feature set, were further investigated in the patient radiomics modeling.

2. Lesion overall response and progression modeling studies

(1) Univariate analysis

Univariate association between the features (or absorbed dose) and OR classification was investigated using Spearman's rank correlation. Univariate analysis for the features (or absorbed dose) and progression was investigated by Cox regression.

(2) Multivariate analysis – modified Bo-LASSO

In order to select robust features, build generalized models and evaluate unbiased model performance, a nested cross-validation (CV) framework has been employed (details are shown in Fig. 1). In the outer loop, 10 times 5-fold cross validation was used to estimate the model performance. On the training set of each inner loop, $N$ times bootstrap was performed. For each resampling training set, optimal lambda hyper-parameter for LASSO was tuned by another cross-validation process. Subsequently, features with non-zero coefficients were recorded. With $N$ resampled training sets, $N$ sets of features were recorded. The frequency of a certain feature being selected by LASSO was calculated and thus a ranking list of the features was obtained. Then, $M$ times bootstrap logistic regression modeling was used to estimate the model order. Specifically, models
using top $i \ (i = 1, \ldots, n = \text{number of features})$ ranked features were developed and mean AUC/c-index for each model order with confidence interval was obtained and the model order corresponding to highest AUC/c-index within one standard error was selected [37]. After we obtained the model order and top selected features, final model in each outer loop was obtained by retraining on the training set and applied on the outer test set (Here, $N$ and $M$ were both 100).

With the developed method, models were constructed using the 15 robust radiomics features set, lesion volume and mean absorbed dose (AD) (15+1+1=17). Since there are two subgroups in this patient cohort, the developed models were applied to both subgroups to assess if the tumor response correlated differently for primary HCC and metastatic lesions. The ROC curve (AUC) and c-index were used to evaluate the lesion OR and progression model performance, respectively. The confidence intervals were calculated by the bootstrap method [38]. The statistical analysis was performed using MATLAB R2019a and RStudio 1.1.463. The Bonferroni correction was applied to account for the family-wise error rate [39]. Overall, 17 features (dose + volume +15 radiomics features) were tested; therefore, p-values < 0.05/17=0.003 was considered significant. For the whole set of features (dose + volume + 45 radiomics features), p-values < 0.05/47=0.001 were considered significant. Meanwhile, due to the existence of unbalance in the dataset, especially for progression analysis (events 14/103), Adaptive Synthetic Sampling Approach (ADASYN) was applied for the multivariate analysis to see if it can improve the performance [40].

**Results**

**Phantom based reproducibility and robustness of radiomics features**

Supplemental Table 3 shows the mean CCC values from the liver phantom radiomics studies, assessed over the 5 repeat scans, OS-EM iterations 1/2, with/without Gaussian filtering and across all conditions (scans and parameters). CCC for sphericity is always 1 because the shape feature does not depend on the PET scan. There are in total 15 features that have mean CCC > 0.85: 1 global feature sphericity, 1 GLCM feature correlation, 2 GLRLM features grey level nonuniformity (GLN), and run length nonuniformity (RLN), 7 GLSZM features large zone emphasis (LZE), grey level nonuniformity (GLN), zone size nonuniformity (ZSN), zone percentage (ZP), large zone low grey level emphasis (LZLGE), large zone high grey level emphasis (LZHGE), grey level variance (GLV), 4 NGTDM features coarseness, busyness, complexity and strength. The average CCCs for repeatability (same conditions, different scans) and reproducibility (different iterations and filtering) have similar results as shown in Supplemental Table 3. Comparing with the mean CCC for both repeatability and reproducibility, there is 1 more robust feature for repeatability (dissimilarity), 6 more robust features (variance, contrast, dissimilarity, LGRE, SRLGE, GLV,GLRLM) and 2 less robust features (LZHGE, GLV_GLSZM) for different iterations, 2 less robust features (ZSN, LZHGE) for with/without filtering.

**Lesion dosimetry and outcome data**

A total of 105 lesions > 2 mL were segmented. The average lesion volume was 45 mL (median:10 ml, range:2 - 833). The average lesion absorbed dose was 336 Gy (median: 265, range:1-1271). The response rate according to RECIST applied at the lesion level was 31% (32/105). The number of metastasis and primary HCC lesions are 70 and 35, respectively, with lesion specific response rate being 26% (9/35) and 33% (23/70)
for the 2 groups. There are 103 lesions that have progression data, two metastatic lesions were excluded due to lack of follow-up. The number of progression events for all the lesions was 14 (4 HCC, 10 metastatic). The mean time-to-event are 322 days (median: 229 days, range: 44-1174 days). The mean time-to-event was 342 days (median: 309, range: 50-1174) for metastatic lesions and 284 days (median: 199 days, range: 44-860 days) for HCC. Kaplan Meier analysis showed that the time to progression for HCC and metastasis was not statistically significantly different (P=0.49)

**Outcome models: Radiomics, absorbed dose, and combined models**

**Univariate analysis**

The univariate results for volume, radiomics features and absorbed dose are shown in Supplemental Table 2 and Table 1 (with Supplemental Table 2 showing all the features and Table 1 showing only the 15 robust radiomics features). These are the Spearman correlation between specific features (or absorbed dose) and OR, and the univariate Cox regression results for progression. Volume has been shown to correlate with patient prognosis for different cancer types [41]. In our study, the Spearman coefficients of volume in terms of OR is -0.215 (p-value = 0.028). Among the 46 radiomics features (including volume), 10 features are significant (p-value < 0.001) for OR: 2/9 GLCM features, 3/13 GLRLM features, 4/13 GLSZM features and 1/5 NGTDM features. Among the 15 robust radiomics features, 8 features are significant for OR: LZE (p-value= 0.0005), ZP (p-value= 0.0004), LZLGE (p-value= 0.001), LZHGE (p-value= 0.002), GLV (p-value= 0.0009), Coarseness (p-value= 0.003), Busyness (p-value= 0.001), and Strength (p-value= 0.003). Absorbed dose is a significant predictor of the OR (p-value= 0.0003). In comparison, among the 46 radiomics features (including volume), no features are significant for progression. ZSN, a robust feature, is the most significant one (p-value= 0.063) for progression. Absorbed dose is a marginally significant predictor for progression (p-value= 0.005).

Inter-feature correlation is shown in the correlation heat map of Fig. 2. GLN, RLN, LZE, LZHGE are highly correlated with volume (Spearman coefficients > 0.85). In general, the radiomics features are highly correlated with each other (except sphericity). Though most of the radiomics features are still significantly correlated with dose (except sphericity, GLN, and ZSN), the correlation of radiomics features with dose is generally lower than radiomics features amongst them, as shown in Table 1.

**Table 1 Summary of statistical analysis for volume, the 15 robust radiomics features and absorbed dose with Bonferroni correction.**
### Multivariate analysis

Given the limited sample size, we included both primary and metastasis cases in the modeling. For the subset of robust features, the model order is 2 for both OR and progression endpoints, with top 2 features for OR being absorbed dose and zone percentage (ZP), and for progression being absorbed dose and ZSN. Fig. 3 shows the model order determination for the robust features and absorbed dose. The top 5 features are shown in Table 2 for OR and progression models. (Model order determination and the top 5 features using all the radiomics features and absorbed dose are presented in the supplemental materials Fig. 1 and table 4).

After the model order and top features were decided, nested cross-validation was applied to estimate the performance of the final model. The results for models with ZP only, ZSN only, absorbed dose only and the combined models (radiomics robust + dose) are listed in Table 3. When considering the entire cohort, for the combined models the average AUCs for OR (0.729 (95% CI: 0.702-0.758)), and the average c-indexes for progression (0.803 (95% CI: 0.790-0.815) are superior to the corresponding values for the absorbed dose only and ZP/ZSN only models. The results for the subgroups of primary and metastasis cases are shown in Table

| Features         | Spearman correlation with absorbed dose | P value for dose correlation | Spearman correlation with OR | P value for OR | C-index for progression | Hazard Ratio for progression | P value for progression |
|------------------|----------------------------------------|-----------------------------|------------------------------|---------------|------------------------|------------------------------|--------------------------|
| Volume           | -0.262                                 | 0.007                       | -0.215                       | 0.028         | 0.565                  | 0.282                        | 0.417                    |
| Global Sphericity| 0.061                                  | 0.539                       | 0.142                        | 0.148         | 0.590                  | 0.728                        | 0.313                    |
| GLCM Correlation | -0.340                                 | 3.882e-4                    | -0.216                       | 0.027         | 0.438                  | 1.019                        | 0.950                    |
| GLRLM GLN        | -0.362                                 | 1.45e-4                     | -0.269                       | 0.006         | 0.600                  | 0.297                        | 0.323                    |
| GLRLM RLN        | -0.252                                 | 0.010                       | -0.236                       | 0.015         | 0.639                  | 0.213                        | 0.201                    |
| GLSZM LZE        | -0.482                                 | 1.989e-7                    | -0.333                       | 0.0005        | 0.562                  | 0.415                        | 0.629                    |
| GLSZM GLN        | -0.078                                 | 0.427                       | -0.121                       | 0.218         | 0.734                  | 0.326                        | 0.088                    |
| GLSZM ZSN        | -0.057                                 | 0.565                       | -0.081                       | 0.412         | 0.752                  | 0.358                        | 0.063                    |
| GLSZM ZP         | 0.483                                  | 1.828e-7                    | 0.341                        | 0.0004        | 0.491                  | 0.804                        | 0.502                    |
| GLSZM LZLGE      | -0.548                                 | 1.485e-9                    | -0.317                       | 0.001         | 0.460                  | 0.872                        | 0.760                    |
| GLSZM LZHGE      | -0.293                                 | 0.002                       | -0.300                       | 0.002         | 0.676                  | 0.006                        | 0.348                    |
| GLSZM GLV        | 0.467                                  | 5.104e-7                    | 0.320                        | 0.0009        | 0.549                  | 0.491                        | 0.136                    |
| NGTDM Coarseness | 0.379                                  | 6.789e-5                    | 0.285                        | 0.003         | 0.601                  | 1.027                        | 0.930                    |
| NGTDM Busyness   | -0.509                                 | 2.862e-8                    | -0.307                       | 0.001         | 0.482                  | 0.522                        | 0.585                    |
| NGTDM Complexity | 0.324                                  | 7.596e-4                    | 0.244                        | 0.012         | 0.609                  | 1.124                        | 0.657                    |
| NGTDM Strength   | 0.245                                  | 0.012                       | 0.284                        | 0.003         | 0.669                  | 1.110                        | 0.321                    |
| DOSE Mean        | NA                                     | NA                          | 0.345                        | 0.0003        | 0.819                  | 0.121                        | 0.005                    |
3 as well. For the OR model in the subgroup of HCC, the radiomics only model shows the best performance with average AUC of 0.762 (95% CI: 0.680-0.834), and in the subgroup of metastasis, the absorbed dose only model shows the best performance with average AUC of 0.696 (95% CI: 0.654-0.737). However, for the progression analysis, in both subgroups the combined model outperforms the individual models. The ROC curve for OR using radiomics alone, dose alone and combined models is shown in Fig. 4, and the Kaplan-Meier plot for progression for the combined models is shown in Fig. 5, respectively. Log-rank test was used for the comparison of high and low risk groups for progression. The cutoff was median value of the predicted Cox survival probability. The weights of OR model and progression models are shown below. Artificially increasing the number of cases using ADASYN was evaluated as well, but found no substantial difference.

OR model (Generalized linear regression model):

\[
\text{logit}(y) \sim -0.892 + 0.520ZP + 0.488\text{Dose}
\]

Distribution = Binomial

Progression Cox model:

\[
h(t) \sim h_0(t) \exp(-0.530ZSN + -1.707\text{Dose})
\]

Table 2. Top 5 features for the combined models with robust radiomics features, volume and absorbed dose

| OR        | Progression |
|-----------|-------------|
| Mean absorbed dose | Mean absorbed dose |
| ZP        | ZSN         |
| Sphericity| Strength    |
| GLV       | Complexity  |
| Coarseness| Sphericity  |

Table 3. Average AUC/c-index for individual and combined models with all the lesions, HCC lesions and metastasis lesions

| OR Model         | Average AUC (95 % confidence intervals) |
|------------------|----------------------------------------|
|                  | All (105) | Primary HCC (35) | Metastasis (70) |
| Radiomics (ZP)   | 0.713 (0.685-0.741) | 0.762 (0.680-0.834) | 0.658 (0.623-0.693) |
| Absorbed Dose    | 0.713(0.678-0.746) | 0.717 (0.642-0.786) | 0.696 (0.654-0.737) |
| Combined (Dose + ZP) | 0.729 (0.702-0.758) | 0.734 (0.660-0.802) | 0.692 (0.653-0.723) |

| Progression Model | Average c-index (95 % confidence intervals) |
|-------------------|---------------------------------------------|
|                  | All (103) | Primary HCC (35) | Metastasis (68) |
| Radiomics (ZSN)   | 0.694 (0.676-0.710) | 0.565 (0.528-0.598) | 0.656 (0.629-0.680) |
| Absorbed Dose     | 0.754 (0.742-0.766) | 0.613 (0.585-0.635) | 0.719 (0.700-0.737) |
| Combined (Dose+ZSN)| 0.803 (0.790-0.815) | 0.638 (0.610-0.661) | 0.762 (0.740-0.780) |

Discussion
Uncovering robust radiomics features is an important task for building robust models for identifying responders and non-responders and prediction of cancer progression. Thus, radiomics features extracted from repeated PET scans, different number of OS-EM PET iterations, with/without Gaussian post-filtering were evaluated for robustness using CCC. Despite the higher noise associated with $^{90}$Y PET compared with FDG PET, 15 radiomics features were identified as robust with CCC > 0.85. In general, the robust features for different scans (repeatability), OS-EM iterations 1/2 and with/without filtering largely overlap, which indicates that robust features tend to be consistent for different imaging settings. The results also showed that more features are robust to different iteration setting and less features are robust to application of Gaussian filtering. In a study of intratumor FDG PET uptake heterogeneity quantification by Hatt et al., zone percentage (ZP) was found to be robust with respect to the delineation method used and the partial volume effects. This feature also demonstrated high differentiation power for prediction of response in esophageal carcinoma [42]. In a study by Doumou et al., ZP presented substantial agreement across different segmentation and different levels of smoothing [43]. A study by Ashrafinia et al. showed that ZSN extracted from $^{99}$Tc-Sestamibi Myocardial-Perfusion SPECT (MPS) images showed high reproducibility [44]. Another recent study by Li et al. on FDG PET radiomics analysis, showed that ZSN is a stable feature [45]. The phantom repeatability and reproducibility study provides robust features for further radiomics modeling that has the potential to generalize to PET images reconstructed at other institutions where different reconstruction settings might have been applied. While this phantom study focused on reconstruction settings, there are other sources of variability as mentioned that we didn't evaluate here, such as segmentation, interpolation, preprocessing, which are investigated in other literatures [22, 23, 33, 46] and reviewed in [47, 48]

The aim of this work is to find radiomics signature that can facilitate dose metrics in the prediction of tumor response. The final model order is small being 2 (dose+ZP and dose+ZSN), which is reasonable considering the high correlation between most radiomics features (Figure 2). The correlation between ZP and absorbed dose is 0.483 (p-value = 1.828e-7) and ZSN and absorbed dose is -0.057 (p-value= 0.565) (Table 1), which indicates that ZSN could provide more complementary information to the combined model than ZP. This is consistent with the substantial higher c-index for the combined absorbed dose and ZSN model (0.803) compared with ZSN only (0.694) and absorbed dose only (0.754) models for progression, but only slightly higher AUC for the combined absorbed dose and ZP model (0.729) compared with the ZP only (0.713) and absorbed dose only (0.713) models for OR (Table 3). In Fig. 4, the ROC curves for radiomics alone, dose alone and combined models did present some overlap. However, it still showed consistent trends in the data, that the combined model performs better than individual models. Access to larger Y-90 PET imaging data sets is required to independently validate these findings and to reach statistical significance for the improvement of the performance of the combined model over the individual models. Further studies, such as obtaining radiomics features from FDG-PET, CT, or MRI, could potentially add more complementary information and further improve the performance [49].

ZP is a feature from GLSZM matrix, quantifying the coarseness of the texture by the ratio of number of zones and number of voxels. The higher the value is, the finer the texture is, and according to our results the higher the probability the tumor will respond. Fig. 6 (a), (b) show example lesions with large/small ZP, that were classified as responder/non-responder; (c), (d) show lesions with large/small ZSN, that did not progress for a long follow-up time (1174 days) and progressed in a short time (44 days). Smaller ZP values correspond to
coarser appearance and worse response. In another study by Ha et al, ZP was one of the features used to characterize locally advanced breast cancer [50]. The trend is consistent with what we found in our study, that larger ZP is associated with better response. ZSN measures the variability of size zone volumes in the ROIs, higher the value, larger the variance of the size zone volumes. The hazard ratio for ZSN is smaller than 1, which means the higher the ZSN, the better the lesion prognosis.

The modified LASSO method we developed was inspired by R. Bach's work on Bolasso, which showed that the Lasso selects all the variables that should enter the model with probability tending to one exponentially fast [51]. So, if we run the Lasso for multiple bootstrapped replications of a given sample, then intersecting the supports of the Lasso (i.e., non-zero coefficients) leads to consistent model selection. However, the direct application failed since the intersection of the supports lead to null for some datasets. Bunea et al. came up with similar variants of bootstrap enhanced LASSO (BE-LASSO) [52]. The percentage of times each predictor was selected (variable inclusion probability) was recorded and user-defined threshold (50%) was used to determine the variables. V. Abram et al. built upon Bunea's method of Be-LASSO [53]. Instead of user-defined probability for feature selection, they used the quantiles of the bootstrap distribution of the coefficients of variables to determine the significance of that variable. In our study, we developed a new way to select features, still based on the bootstrap LASSO. Instead of using predefined probability or the distribution quantile, we obtained a ranking of the features based on the frequency of being selected in the bootstrap, then, we performed cross validation to calculate the AUC/c-index vs. number of top features included in the model. In this way, we obtained the most parsimonious model, which is desired when small sample size is unavoidable.

In summary, absorbed dose is a strong predictor for tumor control, both in terms of OR at first follow-up and time to progression, which is consistent with recent reports [14-16]. The radiomics feature signals the complimentary value of texture to improve the absorbed dose only model prediction. It is interesting to explore the underlying biological mechanism of the reason for higher ZP and ZSN leading to better prognosis, which should be investigated on larger dataset in the future. The two features model can be interpreted as: given the dose being fixed, the change in ZP/ZSN will help to predict tumor control (OR/progression). Using this information, additional attentions would be given to the lesions that possess lower ZP/ZSN value, which have a higher risk of failure (in terms of OR/progression), which is potentially informative for clinical decisions. Immediate prediction of response, based on radiomics features and dose metrics both of which can be derived from $^{90}$Y PET/CT performed immediately after RE, has clinical utility. Instead of waiting for the first follow up morphologic imaging that typically occurs at $> 2$ months, the potential to predict non-responding lesions immediately after therapy would facilitate adaptive therapy to selected lesions where $^{90}$Y RE is followed by further treatment such as stereotactic body radiation therapy or microwave ablation.

Limitation of our study include the heterogeneous patient cohort and the small sample size. Patient $^{90}$Y imaging data is scarce because post-therapy imaging is not routinely performed after RE, but studies reporting $^{90}$Y SPECT/CT and PET/CT imaging is rising and is expected to become more readily available, enabling studies with larger cohorts.

**Conclusion**
In this study, radiomics only, absorbed dose only and combined models showed predictive ability for tumor OR and progression in $^{90}$Y radioembolization patients. The final tumor OR model consisting of the robust radiomics feature ZP and mean absorbed dose achieved a nested CV AUC 0.729 while the final progression model consisting of the robust radiomics feature ZSN and mean absorbed dose achieved a c-index of 0.803. Further validation on large external cohorts will be necessary for clinically applicable models. Nonetheless, this study showed the potential of combining $^{90}$Y PET derived radiomics and absorbed dose for improved model building to predict tumor OR and progression in $^{90}$Y radioembolization treatment.

**Declarations**

**Data Availability** Anonymized $^{90}$Y PET/CT DICOM data including segmented lesions for select patients are available at the University of Michigan Library Deep Blue repository:

https://doi.org/10.7302/v07v-z854

Radiomics extraction code implemented in this work is shared under the GNU General Public License at: https://github.com/mvallieres/radiomics.

**Funding** This work was supported by grants R01-CA233487 awarded by the National Cancer Institute (NCI) and grant R01-EB022075 awarded by the National Institute of Biomedical Imaging (NIBIB), United States Department of Health and Human Services.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Informed consent** Informed consent was obtained from all individual participants included in the study.

**Contributions** LW conducted data organization, statistical analysis, manuscript writing and contributed to the study design. CC and JX performed phantom experiments and radiomics feature extraction. RK identified and segmented lesions on patient images. YD and IE contributed to the study design and manuscript writing. All authors read and approved the final manuscript.

**References**

1. Kennedy A. Radioembolization of hepatic tumors. J Gastrointest Oncol. 2014;5:178.
2. Gans JH, Lipman J, Golowa Y, Kinkhabwala M, Kaubisch A. Hepatic Cancers Overview: Surgical and Chemotherapeutic Options, How Do Y-90 Microspheres Fit in? Semin Nucl Med: Elsevier; 2019.
3. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2015;278:563-77.
4. Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nature communications. 2014;5:4006.

5. Lambin P, Leijenaar RT, Deist TM, Peerlings J, De Jong EE, Van Timmeren J, et al. Radiomics: the bridge between medical imaging and personalized medicine. Nature reviews Clinical oncology. 2017;14:749.

6. Vallières M, Freeman CR, Skamene SR, El Naqa I. A radiomics model from joint FDG-PET and MRI texture features for the prediction of lung metastases in soft-tissue sarcomas of the extremities. Phys Med Biol. 2015;60:5471.

7. Zhang B, Tian J, Dong D, Gu D, Dong Y, Zhang L, et al. Radiomics features of multiparametric MRI as novel prognostic factors in advanced nasopharyngeal carcinoma. Clin Cancer Res. 2017;23:4259-69.

8. Li H, Zhu Y, Burnside ES, Huang E, Dukker K, Hoadley KA, et al. Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. NPJ breast cancer. 2016;2:16012.

9. Veit-Haibach P, Buvat I, Herrmann K. EJNMMI supplement: bringing AI and radiomics to nuclear medicine. Springer; 2019.

10. Morin O, Vallières M, Jochems A, Woodruff HC, Valdes G, Braunstein SE, et al. A deep look into the future of quantitative imaging in oncology: a statement of working principles and proposal for change. International Journal of Radiation Oncology* Biology* Physics. 2018;102:1074-82.

11. Visvikis D, Le Rest CC, Jaouen V, Hatt M. Artificial intelligence, machine (deep) learning and radio (geno)mics: definitions and nuclear medicine imaging applications. Eur J Nucl Med Mol Imaging. 2019:1-8.

12. Blanc-Durand P, Van Der Gucht A, Jreige M, Nicod-Lalonde M, Silva-Monteiro M, Prior JO, et al. Signature of survival: a 18F-FDG PET based whole-liver radiomic analysis predicts survival after 90Y-TARE for hepatocellular carcinoma. Oncotarget. 2018;9:4549.

13. Gensure RH, Foran DJ, Lee VM, Gendel VM, Jabbour SK, Carpizo DR, et al. Evaluation of hepatic tumor response to yttrium-90 radioembolization therapy using texture signatures generated from contrast-enhanced CT images. Acad Radiol. 2012;19:1201-7.

14. Fowler KJ, Maughan NM, Laforest R, Saad NE, Sharma A, Olsen J, et al. PET/MRI of hepatic 90Y microsphere deposition determines individual tumor response. Cardiovasc Intervent Radiol. 2016;39:855-64.

15. Srinivas SM, Natarajan N, Kuroiwa J, Gallagher S, Nasr E, Shah SN, et al. Determination of radiation absorbed dose to primary liver tumors and normal liver tissue using post-radioembolization 90Y PET. Front Oncol. 2014;4:255.

16. Chan KT, Alessio AM, Johnson GE, Vaidya S, Kwan SW, Monsky W, et al. Prospective Trial using internal pair-production positron emission tomography to establish the yttrium-90 radioembolization dose required for response of hepatocellular carcinoma. International Journal of Radiation Oncology* Biology* Physics. 2018;101:358-65.

17. Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, Kaseb A, Mahvash A. Hepatocellular Carcinoma Tumor Dose Response After 90Y-radioembolization With Glass Microspheres Using 90Y-
SPECT/CT-Based Voxel Dosimetry. International Journal of Radiation Oncology* Biology* Physics. 2018;102:451-61.

18. Dewaraja YK, Devasia T, Kaza RK, Mikell JK, Owen D, Roberson PL, et al. Prediction of tumor control in 90Y radioembolization by logit models with PET/CT based dose metrics. J Nucl Med. 2019:jnumed. 119.226472.

19. Pasciak AS, Bourgeois AC, McKinney JM, Chang TT, Osborne DR, Acuff SN, et al. Radioembolization and the dynamic role of 90Y PET/CT. Front Oncol. 2014;4:38.

20. Willowson KP, Tapner M, Bailey DL. A multicentre comparison of quantitative 90 Y PET/CT for dosimetric purposes after radioembolization with resin microspheres. Eur J Nucl Med Mol Imaging. 2015;42:1202-22.

21. Robinson K, Li H, Lan L, Schacht D, Giger M. Radiomics robustness assessment and classification evaluation: A two-stage method demonstrated on multivendor FFDM. Med Phys. 2019;46:2145-56.

22. Traverso A, Wee L, Dekker A, Gillies R. Repeatability and reproducibility of radiomic features: a systematic review. International Journal of Radiation Oncology* Biology* Physics. 2018;102:1143-58.

23. Zwanenburg A. Radiomics in nuclear medicine: robustness, reproducibility, standardization, and how to avoid data analysis traps and replication crisis. Eur J Nucl Med Mol Imaging. 2019;46:2638-55.

24. Waninger J, Green M, Cheze CLR, Rosen B, EI IN. Integrating radiomics into clinical trial design. The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine (AIMN)[and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of. 2019.

25. Zwanenburg A, Leger S, Agolli L, Pilz K, Troost EG, Richter C, et al. Assessing robustness of radiomic features by image perturbation. Sci Rep. 2019;9:1-10.

26. El Naqa I, Grigsby PW, Apte A, Kidd E, Donnelly E, Khullar D, et al. Exploring feature-based approaches in PET images for predicting cancer treatment outcomes. Pattern recognition. 2009;42:1162-71.

27. Ohri N, Duan F, Snyder BS, Wei B, Machtay M, Alavi A, et al. Pretreatment 18F-FDG PET textural features in locally advanced non–small cell lung cancer: Secondary analysis of ACRIN 6668/RTOG 0235. J Nucl Med. 2016;57:842-8.

28. Zwanenburg A, Leger S, Vallières M, Löck S. Image biomarker standardisation initiative. arXiv preprint arXiv:161207003. 2016.

29. Hatt M, Majdoub M, Vallières M, Tixier F, Le Rest CC, Groheux D, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi–cancer site patient cohort. J Nucl Med. 2015;56:38-44.

30. El Naqa I. The role of quantitative PET in predicting cancer treatment outcomes. Clinical and translational imaging. 2014;2:305-20.

31. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-16.

32. Lin L. A Concordance Correlation Coefficient to Evaluate Reproducibility. Biometric, 45, 255-268. 1989.

33. Zhao B, Tan Y, Tsai W-Y, Qi J, Xie C, Lu L, et al. Reproducibility of radiomics for deciphering tumor phenotype with imaging. Sci Rep. 2016;6:23428.
34. Fave X, Mackin D, Yang J, Zhang J, Fried D, Balter P, et al. Can radiomics features be reproducibly measured from CBCT images for patients with non-small cell lung cancer? Med Phys. 2015;42:6784-97.

35. Hu P, Wang J, Zhong H, Zhou Z, Shen L, Hu W, et al. Reproducibility with repeat CT in radiomics study for rectal cancer. Oncotarget. 2016;7:71440.

36. van Timmeren JE, Leijenaar RT, van Elmpt W, Wang J, Zhang Z, Dekker A, et al. Test–retest data for radiomics feature stability analysis: generalizable or study-specific? Tomography. 2016;2:361.

37. Friedman J, Hastie T, Tibshirani R. The elements of statistical learning: Springer series in statistics New York; 2001.

38. DiCiccio TJ, Efron B. Bootstrap confidence intervals. Statistical science. 1996:189-212.

39. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med. 1990;9:811-8.

40. Haibo H, Yang B, Edwardo GA, Shutao L. Adaptive Synthetic Sampling Approach for Imbalanced Learning. IEEE International Joint Conference on Neural Networks, IJCNN; 2016. p. 1322-8.

41. Brooks FJ, Grigsby PW. The effect of small tumor volumes on studies of intratumoral heterogeneity of tracer uptake. J Nucl Med. 2014;55:37-42.

42. Hatt M, Tixier F, Le Rest CC, Pradier O, Visvikis D. Robustness of intratumour 18 F-FDG PET uptake heterogeneity quantification for therapy response prediction in oesophageal carcinoma. Eur J Nucl Med Mol Imaging. 2013;40:1662-71.

43. Doumou G, Siddique M, Tsoumpas C, Goh V, Cook GJ. The precision of textural analysis in 18 F-FDG-PET scans of oesophageal cancer. Eur Radiol. 2015;25:2805-12.

44. Ashrafinia S, Ghazi P, Marcus CV, Taghipour M, Yan R, Valenta I, et al. Robustness and Reproducibility of Radiomic Features in 99mTc-Sestamibi SPECT imaging of Myocardial Perfusion. Med Phys: WILEY 111 RIVER ST, HOBOKEN 07030-5774, NJ USA; 2017.

45. Li Y, Jiang J, Lu J, Jiang J, Zhang H, Zuo C. Radiomics: a novel feature extraction method for brain neuron degeneration disease using 18F-FDG PET imaging and its implementation for Alzheimer’s disease and mild cognitive impairment. Ther Adv Neurol Disord. 2019;12:1756286419838682.

46. Parmar C, Velazquez ER, Leijenaar R, Jermoumi M, Carvalho S, Mak RH, et al. Robust radiomics feature quantification using semiautomatic volumetric segmentation. PLoS One. 2014;9.

47. Zwanenburg A, Vallières M, Abdalah MA, Aerts HJ, Andreachczyk V, Apte A, et al. The Image Biomarker Standardization Initiative: standardized quantitative radiomics for high-throughput image-based phenotyping. Radiology. 2020;295:328-38.

48. Avanzo M, Stancanello J, El Naqa I. Beyond imaging: the promise of radiomics. Phys Med. 2017;38:122-39.

49. Wei L, Osman S, Hatt M, El Naqa I. Machine learning for radiomics-based multi-modality and multi-parametric modeling. The quarterly journal of nuclear medicine and molecular imaging: official publication of the Italian Association of Nuclear Medicine (AIMN)[and] the International Association of Radiopharmacology (IAR)[and] Section of the Society of. 2019;63:323.

50. Ha S, Park S, Bang J-I, Kim E-K, Lee H-Y. Metabolic radiomics for pretreatment 18 F-FDG PET/CT to characterize locally advanced breast cancer: histopathologic characteristics, response to neoadjuvant
Figure 1

Summary of radiomics model construction and evaluation.
Figure 2

Spearman correlation heat map for radiomics features, volume and absorbed dose.

Figure 3

Radiomics_robust+dose model order determination for OR (left) and progression (right): average AUC/c-index vs. number of top features included.
Figure 4

ROC curves for overall response (OR) at first follow-up with the combined model, radiomics alone model, and dose alone model.
Figure 5

Kaplan-Meier plot of the combined model for progression (absorbed dose + ZSN). This is the result of 10 times 5-fold cross validation, thus there are more test samples than the dataset. High and low risk lesions for progression were stratified by median value of the Cox model output, with high risk group lesions having shorter time to progression, vice versa.
Figure 6

Example 90Y PET/CT images with CT-defined lesion contours (left: PET/CT axial slice showing the anatomical position within liver, right: magnified lesion on PET). (a) Lesion with large ZP value corresponding to responder; (b) Lesion with small ZP value corresponding to non-responder; (c) lesion with large ZSN value corresponding to no progression at 1174 day; (d) Lesion with small ZSN value corresponding to progression in 44 days.
Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementary.pdf